March 02, 2015 6:15 PM ET


Company Overview of AnorMED Inc.

Company Overview

As of November 7, 2006, AnorMED, Inc. was acquired by Genzyme Corporation. AnorMED, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic drugs for the treatment of hematology, human immunodeficiency virus (HIV), and oncology. Its lead drug product candidate include MOZOBIL, which is under phase III clinical trial is used for cancer patients undergoing stem cell transplantation; and AMD070, which is under phase Ib/IIa trial is used as a HIV entry inhibitor. The company also develops MOZOBIL and CXCR4, which are in preclinical trials for the treatment of oncology; and CCR5, which is a preclinical trial product used for the treatment of ...

20353 - 64th Avenue

Suite 200

Langley, BC V2Y 1N5


Founded in 1996

142 Employees



Key Executives for AnorMED Inc.

AnorMED Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Eupraxia Pharmaceuticals Inc. Americas
Gvest, Inc. Americas
DSM Biologics Holding, Inc. Americas
1506369 Alberta Ulc Americas
Thrasos Innovation Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AnorMED Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at